pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
408
stories
13d
Latigo IPO raises nearly $350M for pain drug development
biopharma dive
13d
Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy
fiercebiotech
14d
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
14d
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
14d
Chutes & Ladders—BioNTech brings in Sobi CEO
fiercebiotech
14d
With $263M, LifeMine unearths a new drug for organ transplants
biopharma dive
14d
Sanofi pauses mid-stage lung study amid new CEO’s ‘rigorous portfolio prioritization’
biospace
14d
Opinion: One year since Kennedy canceled mRNA vaccine projects, science shows how wrong he was
stat
14d
LifeMine raises $263M in mission to improve organ transplant aftercare
biospace
15d
Opinion: What my colleagues and I will look for as we assess U.S. measles elimination status
stat
15d
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
15d
‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
fiercebiotech
15d
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
fiercebiotech
15d
STAT+: Moderna launches early trial of Ebola mRNA vaccine
stat
15d
Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
biospace
15d
Novo CEO sees innovation as a matter of survival amid pipeline setbacks
biospace
15d
Attovia extends biotech IPO streak with $289M listing for three I&I drugs
endpoints
16d
MRI is standard for diagnosing prostate cancer in most western countries. But most U.S. men don’t get them
stat
16d
5 NextGen winners who went public this year (and which ones are hiring)
biospace
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
16d
Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-up
fda medwatch
16d
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
16d
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
16d
Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey
fiercebiotech
17d
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
biopharma dive
17d
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
17d
Boticelli Foods Recalls Bettergoods Pistachio Nut Butter Because of Possible Health Risk
fda recalls
17d
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
17d
Novo’s late-stage IL-6 stumble shakes inflammation space
biospace
20d
AbbVie touts strong momentum for Skyrizi despite rising competition
endpoints
← prev
page 3 of 14
next →
